Who are AG regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dose dense AC, TC chemotherapy, TC, AG chemotherapy, IV Chemotherapy (Regimen 1), Modified Bolus 5-FU/LV with Irinotecan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ag-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AG regimen — Competitive Intelligence Brief

AG regimen (AG regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination regimen. Area: Oncology.

phase 3 Chemotherapy combination regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AG regimen (AG regimen) — Tianjin Medical University Cancer Institute and Hospital. AG regimen is a chemotherapy combination regimen, typically consisting of adriamycin (doxorubicin) and gemcitabine, that works by damaging cancer cell DNA and inhibiting nucleotide synthesis to kill rapidly dividing cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AG regimen TARGET	AG regimen	Tianjin Medical University Cancer Institute and Hospital	phase 3	Chemotherapy combination regimen
Dose dense AC	Dose dense AC	Ottawa Hospital Research Institute	marketed	Chemotherapy combination regimen
TC chemotherapy	TC chemotherapy	Agendia	marketed	Chemotherapy combination regimen
TC	TC	AGO Study Group	marketed	Chemotherapy combination regimen
AG chemotherapy	AG chemotherapy	Zhejiang Cancer Hospital	phase 3	Chemotherapy combination regimen
IV Chemotherapy (Regimen 1)	IV Chemotherapy (Regimen 1)	UNICANCER	phase 3	Chemotherapy combination regimen
Modified Bolus 5-FU/LV with Irinotecan	Modified Bolus 5-FU/LV with Irinotecan	Pfizer	phase 3	Chemotherapy combination regimen	Thymidylate synthase (5-FU), Topoisomerase I (irinotecan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination regimen class)

Tianjin Medical University Cancer Institute and Hospital · 2 drugs in this class
Agendia · 1 drug in this class
Asan Medical Center · 1 drug in this class
Children's Cancer Group, China · 1 drug in this class
China Breast Cancer Clinical Study Group · 1 drug in this class
Fujian Medical University · 1 drug in this class
MIPO Clinic · 1 drug in this class
Nanjing Yoko Biomedical Co., Ltd. · 1 drug in this class
Ottawa Hospital Research Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AG regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-regimen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab